Proxygen’s molecular glue ambitions are continuing to take shape as the Austrian biotech sticks together a third licensing deal in less than three years.
The company has signed a licensing agreement with Merck & Co. worth more than $2.55 billion in biobucks, according to an announcement Wednesday. How much the biotech is receiving upfront, or how many targets it is offering the U.S. Big Pharma, remains undisclosed.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,